Krystal Biotech, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| KRYS | BHVN | BBIO | IDYA | BMRN | KOD | |
|---|---|---|---|---|---|---|
| Market cap | 9.83B | 1.78B | 12.85B | 3.48B | 10.72B | 6.24B |
| P/E (TTM) | 41.6 | — | — | — | 149.7 | — |
| Forward P/E | 35.8 | -6.3 | 2,275.1 | -9.0 | 8.3 | -28.9 |
| Price/book | 7.2 | 145.8 | -5.1 | 2.9 | 1.7 | 101.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +79.50% | −29.11% | +16.37% | +34.89% | +5.57% | +760.95% |
| Today | +0.14% | −2.24% | +0.61% | −0.14% | +1.09% | −0.61% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All KRYS news ›Krystal Biotech: Vyjuvek's Success Is Becoming Its Growth Problem (Downgrade)
Seeking Alpha - Krystal Biotech is downgraded from Buy to Hold as U.S. VYJUVEK sales plateau and growth shifts ex-U.S. - KRYS's Q2 2026 saw VYJUVEK net revenue at $119.2M, with U.S. sales declining 4.6% Y/Y and ex-U.S. growth offsetting. -…
Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value
Krystal Biotech is rated a 'Buy' due to strong Vyjuvek sales, robust profitability, and a promising pipeline. Read more on KRYS stock here. - Krystal Biotech is rated a 'Buy' due to strong Vyjuvek sales, robust profitability, and a…
Financial Contrast: Krystal Biotech (NASDAQ:KRYS) versus Applied Therapeutics (NASDAQ:APLT)
Posted by Defense World Staff on Oct 12th, 2026 Krystal Biotech (NASDAQ:KRYS – Get Free Report) and Applied Therapeutics (NASDAQ:APLT – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the…
Krystal Biotech rated 'Buy' on strong Vyjuvek sales and promising drug pipeline
Krystal Biotech is rated a 'Buy' due to strong sales of Vyjuvek, a drug approved for dystrophic epidermolysis bullosa (DEB), which generated $119.2 million in Q2 revenue and is expanding globally. The company maintains a strong $1.1…
Krystal Biotech (KRYS) Has a Blockbuster Rare-Disease Drug. Is Its Moat Durable?
Krystal Biotech has already proven that VYJUVEK can become a successful commercial drug, but investors are paying for that success to last far beyond the current opportunity. Krystal Biotech, Inc. (NASDAQ:KRYS) has something most biotech…
ETFs Investing in Krystal Biotech, Inc. Stocks — TradingView
Krystal Biotech, Inc. operates as a biotechnology company, which engages in discovery, development, manufacturing, and commercialization of pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S.…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
seekingalpha.com2
-
bitget.com1
-
defenseworld.net1
-
insidermonkey.com1
-
pluang.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.